GlassScriptPhysician profile
William Palmer
NPI 1285161539
$3,476.20
in general payments reported to CMS, 2019-2025
17 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.46 · 2022: $279 · 2023: $921 · 2024: $861 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379 · Consulting Fee: $480 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.70 |
| Consulting Fee | $480.00 |
| Education | $256.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $891.10 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $522.35 | 2022-2025 | |
| Ascensia Diabetes Care US INC. | $480.00 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $323.86 | 2023-2025 | |
| Janssen Biotech, INC. | $275.99 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $226.40 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $157.77 | 2022-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $134.86 | 2022-2025 | Anzupgo |
| Pfizer INC. | $131.00 | 2022-2025 | |
| Incyte Corporation | $83.01 | 2024-2025 | Opzelura, Opzelura |
| Vyne Pharmaceuticals INC. | $82.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.24 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.05 | 2024 | Sotyktu |
| Astrazeneca Pharmaceuticals LP | $31.55 | 2024 | Airsupra |
| Amgen INC. | $22.93 | 2024 | Otezla |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $19.47 | 2025 | Nemluvio |
| Dermavant Sciences, INC. | $14.16 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.